Research article

Stability indicating liquid chromatography method for the analysis of Vecuronium bromide: study of the degradation profile

Mohamed K. Abd Elrahmana, Ola M. El Houssinib, Diana K. Fahemb,*, Hala E. Zaazaa a

a Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St, Cairo, 11562, Egypt
b National Organisation for Drug Control and Research (NODCAR), 51 Wazaret El-Zeraa St, Agouza P.O. Box 12553, Giza, 35521, Egypt

ARTICLE INFO

Keywords:
Analytical chemistry
Pharmaceutical chemistry
Validation
Vecuronium bromide (VEC)
Forced degradation
RP-LC
MS data

ABSTRACT

Neuromuscular blocker agent namely; Vecuronium bromide (VEC) was quantified through developing a simple reversed phase liquid chromatographic (RP-LC) method, in drug substance and in drug product. The proposed method could quantify VEC in the presence of its degradation products produced from exposing VEC to different stress conditions as recommended by the International Conference on harmonization (ICH) guidelines. Acidic (2M HCl), basic (2M NaOH) hydrolysis, oxidation (3% H2O2), photolysis (UV light at 254nm), and thermal (135 °C) degradation were estimated by exposing the drug substances to different stress conditions. The separation of the drug from its degradation products was successfully conducted on Tracer Extrasil CN (150 × 4.6mm; 5μm) column using O-phosphoric acid (pH6; 0.05M)-acetonitrile (50:50v/v) as mobile phase. The detection and quantification were done with UV detection at 210nm. The validation data were found to be acceptable over a concentration range 10-120 μg/ml. The limit of quantification (LOQ) and detection (LOD) were 8.10 and 2.67 μg/ml, respectively. The proposed method met all criteria for validation in accordance with the International Conference on harmonization (ICH) guidelines. The presented work monitored the degradation profile for VEC under various stress conditions and provided a simple LC method for its routine analysis. The structures of the forced degradation products had been described in details using the MS data and the possible degradation pathways were outlined. Besides, the results obtained from the developed method compared statistically with that of the official method indicating high accuracy and precision.

1. Introduction

Vecuronium bromide (VEC) 1-[(2β, 3α, 5α, 16β, 17β)-3, 17-Bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl]-1-methylpiperidinium bromide Figure 1 [1], is an aminosteriodal competitive neuromuscular blocking agent. It was used in general anesthesia as it causes muscle relaxation facilitating endotracheal intubation and to aid controlled ventilation [1, 2]. VEC is official drug where, USP applies LC methods for its determination and quantification in presence of its related substances [3], while BP applies potentiometric method for determination of VEC [4].

To date, all techniques reported for the detection of VEC in biological specimens and drug product involved LC-MS [5, 6, 7, 8, 9], LC with electrochemical detection [10], LC with electrochemical and UVDetection [11], LC with post-column ion-pair extraction using solid phase extraction followed by fluorometric detection [12], ion-pair LC [13], LC and CZE comparative study [14], capillary electrophoresis [15], capillary gas chromatography using nitrogen sensitive detector [16] and mass spectrometry [17, 18, 19]. The specificity of the stability indicating assay methods is investigated by conducting forced degradation studies.

These studies afford a foresight into the possible degradation products of the drug and the degradation pathways and provide explication of the structure of the degradation products. These studies also explain the behavior of the drug towards various stress conditions that aids in the package and development of formulation [20]. No previously reported methods provided a complete degradation study of VEC or determined all the possible degradation products. The present work is concerned with the forced degradation behavior of VEC and the developing a specific stability indicating LC method for its quantification in drug substance and drug product using the International Conference on harmonization (ICH) guidelines of stress-testing [21]. It also suggests the structures of all VEC possible degradation products and explained the expected pathway using the MS data.

* Corresponding author.
E-mail address: donadoctor@yahoo.com (D.K. Fahem).

https://doi.org/10.1016/j.heliyon.2020.e03530
Received 1 May 2019; Received in revised form 29 June 2019; Accepted 28 January 2020
2405-8440/© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. Experimental

2.1. Apparatus

The LC system used was Agilent 1200 series (Germany) equipped with quaternary-pump, column oven, vacuum degasser, UV/VIS detector and 20 μl injector loop. The output signal was processed and monitored using Chemstation software. The column used was Tracer Extrasil CN (150 × 4.6mm; 5μm,China). Injection was done by the aid of Hamilton 50μl syringe (Sigma-Aldrich, Germany). UPLC MS/MS (Waters 3100, USA) equipped with auto sampler (Acquity ultra performance LC), TQ Detector (Acquity ultra performance LC), binary solvent manager pump (Acquity ultra performance LC), and Mass lynx V4.1 software (-ve mode) was used for identification and structure elucidation of the forced degradation products of VEC. Mineralight (UVGL-25) UV lamp (254 nm) was used to prepare photolytic and thermal degradation products, respectively. Other apparatus were used as:Sartorius CP224S balance (Germany), Elma sonic P60 H ultrasonic processor (Germany), pH-meter Jenway 3510 (UK), Memmert water bath (Germany), water purification system Milli-Q® Direct 8/16 system (France) and membrane filters 0.45μm from Teknokroma (Spain).

2.2. Materials and chemicals

Vecuronium bromide reference standard; was supplied by future pharmaceutical industries was certified to be 100.12% according to the official method. Pharmaceutical preparation was fortified at lab to contain 10 mg of VEC in 10 ml vial, 16.25 mg sodium phosphate dibasic anhydrous, 20.75 mg citric acid anhydrous, 97 mg mannitol (to adjust, phosphoric acid and/or sodium hydroxide) and adjust to a pH of 4.

Analytical grade O-phosphoric acid (85%) was purchased from Sigma Aldrich (Germany). HPLC grade acetonitrile was purchased from Macron Advantor performance material Poland S.A. Sodium hydroxide, Hydrogen peroxide (30%), sodium phosphate dibasic anhydrous, citric acid anhydrous and mannitol were purchased from Adwic (El Nasr pharmaceutical chemicals, Cairo, Egypt). Hydrochloric acid was obtained from Riedel-de Haen (Germany). LC grade water was prepared in lab and was filtered through membrane filters 0.45μm.O-phosphoric acid (pH 6; 0.05M) was prepared by dissolving 3.5ml O-phosphoric acid (85%) in 1 L of water adjusting the pH to 6 with NaOH.

2.3. Standard solution

A stock standard solution of VEC (1 mg/ml) was prepared by dissolving an appropriate amount of drug in acetonitrile.

2.4. Forced degradation studies

Intentional degradation was attempted acidic (2MHCl) and basic hydrolysis (2MNaOH), oxidation (3% H2O2), photolysis (UV light at 254 nm) and thermal (135 °C). For acidic, basic hydrolysis and oxidative degradation, the drug was refluxed for 5, 10 and 1 h, respectively. For photolysis and thermal degradation, the study period was 3 h at 254 nm and 2.5 h at 135 °C, respectively. In the forced degradation studies, the drug solutions were prepared by dissolving the standard in a little volume of acetonitrile then complete the volume to 10 ml with either 2MHCl, 2MNaOH, 3% H2O2 or acetonitrile, to yield a concentration of 1 mg/ml of VEC. All solutions were then evaporated on water bath, dissolved in the mobile phase to obtain concentration of 1 mg/ml for VEC. The solutions of acidic and basic hydrolysis were neutralized before evaporation. Degradation products stock solutions were derived from the degradation of 1 mg/ml VEC stock solution.

2.5. Chromatographic conditions

The chromatographic separation was performed on Tracer Extrasil CN (150 × 4.6 mm; 5μm) column maintained at 25 °C using a mobile phase composed of O-phosphoric acid (pH6; 0.05M)-acetonitrile (50:50 v/v). The mobile phase was filtered using a 0.45 μm membrane filter and was pumped at a flow rate of 1 ml/min. The signal was monitored at 210 nm. The run time was 4 min. The chromatographic system and the column were conditioned with the mobile phase for 45 min before injection.

2.6. Procedures

2.6.1. Construction of calibration curve

Into series of 10-ml volumetric flasks, volumes from VEC stock solution (1 mg/ml) were accurately transferred. Then the volume was completed with mobile phase to the mark to obtain a concentration range of (10–120 μg/ml). 20 μl of each concentration was injected three times. The injected concentrations of VEC were plotted against the corresponding peak areas. Linear plot was drawn from which the regression equation was obtained.

2.6.2. Analysis of VEC in pharmaceutical preparation

A concentration of 1 mg/ml was prepared from the vial as stock solution. Suitable aliquots were used to quantify the drug using the previous described procedure.

3. Results

3.1. Chromatographic conditions

Complete separation of VEC from all its forced degradation products was performed on Tracer Extrasil CN (150 × 4.6mm; 5μm) maintained at 25 °C. A mobile phase consisting of O-phosphoric acid (pH6; 0.05M)-acetonitrile (50:50 v/v) was used. The column was conditioned with mobile phase at flow rate of 1 ml/min. The detection and separation between VEC and its forced degradation products was performed on Tracer Extrasil CN (150 × 4.6 mm; 5μm) column maintained at 25 °C using a mobile phase composed of O-phosphoric acid (pH6; 0.05M)-acetonitrile (50:50 v/v). The mobile phase was filtered using a 0.45 μm membrane filter and was pumped at a flow rate of 1 ml/min. The signal was monitored at 210 nm. The run time was 4 min. The chromatographic system and the column were conditioned with the mobile phase for 45 min before injection.

3.2. System suitability

System suitability parameters were studied in order to confirm system performance. These parameters are Resolution (R), capacity factor (k'), Tailing factor (T) and number of theoretical plates (N).
System suitability tests were calculated and results were presented in Table II.

3.3. Identification of the degradation products

Degradation was observed for VEC sample during forced degradation conditions namely; Acidic (2M HCl), basic (2M NaOH) hydrolysis, oxidation (3% H₂O₂) and photolysis (UV light at 254 nm), but it showed high stability towards thermal decomposition (135°C). Figure 3. VEC was unstable towards Acidic (2M HCl), basic (2M NaOH) hydrolysis giving one degradation product (the same tᵣ) (Deg 1). On forced oxidation VEC gave one oxidizable degradation product (Deg 2). Photolytic degradation resulted into the formation of two degradation products (Deg 3, 4). The identification and structure elucidation of all VEC possible degradation products were conducted by the aid of the LC-MS data. Figure 4 Table III. The results of VEC stability studies are summarized in Table IV.

3.4. Application of the proposed LC method to vial analysis

The proposed LC method was applied for the determination of VEC in vials. The results obtained were found to be in agreement with labeled claimed. The obtained recoveries showed that there were no interferences from the excipients in the pharmaceutical product. The mean % recovery of VEC was found to be 100.06% as shown in Table I.

3.5. Method validation

3.5.1. Linearity

The linearity of the developed method was obtained over the concentration range of 10–120 μg/ml for VEC; the linear regression equation was \( y = 5.553x + 115.4 \) with correlation coefficient 0.9996. The results showed that an excellent correlation was found between the peak area and the corresponding concentration of VEC Table I.
Table I. Validation data for the determination of pure VEC using the proposed LC method.

| Parameter                        | RP-LC method |
|----------------------------------|--------------|
| Calibration range (µg/ml)        | 16-120       |
| Linearity                        |              |
| Slope                            | 5.553        |
| Intercept                        | 115.4        |
| Correlation coefficient (r)      | 0.9996       |
| Accuracy (mean ± SD)             |              |
| Drug substance                   | 100.32 ± 1.25|
| Drug product                     | 100.06 ± 1.02|
| Standard added                   | 98.50 ± 0.39 |
| Repeatability (RSD%)             | 0.338        |
| Intermediate precision (RSD%)    | 0.509        |
| LOD (µg/ml)                      | 2.67         |
| LOQ (µg/ml)                      | 8.01         |

Table II. System suitability test for proposed LC method.

| Parameters                      | Obtained value | Reference value [23] |
|---------------------------------|----------------|----------------------|
| Resolution (R)                  | ≥1.5           |                      |
| (VEC/Deg 1)                     | 1.79           |                     |
| (VEC/Deg 2)                     | 1.50           |                     |
| (VEC/Deg 3)                     | 6.82           |                     |
| (VEC/Deg 4)                     | 7.86           |                     |
| Tailing factor (T)              | 1.15           | <2                   |
| Capacity factor (K')            | 1              | 1-10 acceptable      |
| Number of theoretical plates per column (N) | 4499 | Increases with efficiency of the separation |

3.5.2. Accuracy

Percentage recovery of pure VEC expressed the accuracy of the proposed method, which ranged from 99.7-101.5% as shown in Table I. The accuracy of the assay method was also assessed on VEC in its drug product after spiking with pure VEC. The results obtained were listed in Table I. Statistical comparison between the developed method and the official method showed no significant difference Table II.

3.5.3. Precision

Intermediate precision (inter-day variation) and Repeatability (intra-day variation) were checked by analyzing three concentrations of (50, 60 and 70 µg/ml) on three different days and within the same day, respectively. The % RSD values were 0.338% and 0.509% for intra- and inter-day, respectively. This indicated that the proposed method was adequately precise Table I.

3.5.4. Specificity

The proposed method was able to completely detect and discriminate VEC in the presence of all its degradation products formed under various stress conditions as shown from the chromatograms in Figure 2. The proposed method showed a good resolution between VEC and its degradation products indicated the specificity of the proposed method. Besides, the chromatogram obtained by injecting VEC sample solution was found to be identical to the chromatogram obtained by injecting standard drug solution. These results demonstrated the specificity of the proposed method as no interference from the excipients in the pharmaceutical product was observed.

3.5.5. Robustness

The robustness of the developed LC method was examined by making analysis under small variations in experimental conditions. These include; the organic strength percent (±1%), column temperature (±2 °C) and pH (±0.20 units) of the mobile phase. It was found that the method was robust when the organic strength, column temperature and pH of the mobile phase were slightly varied. Results were shown in Table VI.

3.5.6. Limit of detection (LOD) and limit of quantification (LOQ)

The LOQ and LOD were determined as described above to be 8.10 and 2.67 µg/ml, respectively. So, the method could be used to quantify and detect VEC over a very extensive range of concentrations.

4. Discussion

4.1. Optimization of chromatographic conditions

The main target of the proposed LC method was separating of VEC from all its possible degradation products. VEC, Deg 1 and 2 were concluded because of their structural similarity. However Deg 3 and 4 were well separated and eluted away from VEC. In a trial to separate VEC, Deg 1 and 2, different mobile phases with various aqueous and organic ratios were tried. Orthophosphoric acid (pH 6; 0.05 M) played a main role in attaining the separation between VEC, Deg 1 and 2. The pH 6 was found to be suitable for determination of VEC (pKa = 8.97) and its degradation products as basic compounds tended to be ionized (more polar) at pH below their pKa value. So they were more retained on CN columns, which are strong dipoles that attract and separate polar molecules. The more basic compound was the most retained and eluted lastly. So CN (150 × 4.6 mm; 5µm) column was found to be the column for choice for this method. The high molar concentration of Orthophosphoric acid (0.05 M) increased the concentration of hydrogen ion competed for the residual silanol groups on CN columns so reduced peak tailing and retention time. Acetonitrile was chosen as organic modifiers since it was a good solvent for VEC. The mobile phase ratio chosen attained the best resolution of all peaks within optimal run time. The detection was done at 210 nm as a compromise between the maximum absorption of the detected compounds and the very low concentrations of the degradation products with respect to VEC. A flow rate of 1 ml/min was found to be the best possible for the analysis as it provided good resolution of all peaks within less than 4min.

4.2. Forced degradation studies

Stability testing as a component of medication advancement procedure allows us to comprehend the component of a medication’s deterioration. It further aids in acquiring data on chemical and physical factors that leads to instability. The resulting data would help in stabilizing VEC standard or drug product, resulting in expanded shelf-life or enhanced efficacy. According to ICH guideline Q1A (R2), different stress conditions (hydrolysis, oxidation, photolysis, and thermal degradation) were carried out to test the stability of the drug substance to prove the superiority of stability indicating analytical methods [21, 22, 24]. VEC was highly degraded when subjected to basic hydrolysis and oxidative degradation Table IV. So during drug formulation basic excipient must be avoided and the final product had to be packaged under inert atmosphere. Also opaque glass containers were recommended due to the proved drug photosensitivity.

5. Conclusion

In the present contribution, a validated stability indicating LC method was proposed to monitor the degradation profile of VEC under various stress conditions. The drug is found to be liable to acidic and basic hydrolysis, photolysis and oxidation, while it is stable towards thermal degradation. LC/MS was used for the identification and structure elucidation of four degradation products. The proposed LC method providesensitive, accurate and specific stability-indicating method for the
Figure 3. The MS spectra of (A) 2M NaOH, (B) 3% H₂O₂ and (C) Photo (254 nm).
Figure 4. The suggested chemical structure of all possible degradation products.
quantification of VEC in drug substance and in drug product, without any interference from the excipients. The method has been found to be better than previously reported methods as it is highly sensitive, use available chemicals, UV detection, lack of extraction procedures, and short run time. So, it savestime and money and it can be used in routine analysis of VEC.

Declarations

Author contribution statement

Diana Fahem: Performed the experiments; Analyzed and interpreted the data; Wrote the paper.
Mohamed Abd El-Rahman, Ola El-Houssini: Conceived and designed the experiments; Wrote the paper.

Hala Zaazaa: Conceived and designed the experiments; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

References

[1] O. Maryadele, The Merch Index, Merck Research Laboratories: White House Station, 2006, p. 9937.
[2] S.C. Sweetman, Martindale: the Complete Drug Reference, The Pharmaceutical Press, London, 2014, 20, 2040.
[3] United States Pharmacopoeia 40, NF 35, the United States Pharmacopeial Convention Inc., Rockville, MD, 2017, p. 6663.
[4] The British Pharmacopoeia, Her Majesty’s Stationary Office, 2017, p. 1195. London, UK, II.
[5] C.H.M. Kerskes, K.J. Lusthof, P.G.M. Zweipfenning, J.P. Franke, The detection and identification of quaternary nitrogen muscle relaxants in biological fluids and tissues by ion trap LC-ESI-MS, J. Anal. Toxicol. 26 (2002) 29–34.
[6] H. Sayer, O. Quintela, P. Marquet, J. Dupuy, J.M. Gaulier, G. Lachapelle, Identification and quantification of six non-depolarizing neuromuscular blocking agents by LC-MS in biological fluids, J. Anal. Toxicol. 28 (2004) 105–110.
[7] K.D. Ballard, W.E. Vickery, L.T. Nguyen, F.X. Diamond, F. Rieders, An analytical strategy for quaternary ammonium neuromuscular blocking agents in a forensic setting using LC-MS/MS on tandemquadrupole/time-of-flight instrument, J. Am. Soc. Mass Spectrom. 10 (2006) 1457–1468.
[8] K. Usui, T. Hishituma, H. Yamaguchi, T. Saga, T. Wagatsuma, K. Hoshi, N. Tachirii, K. Miura, J. Goto, Simultaneous determination of pancuronium, vecuronium, and their related compounds using LC-ESI-MS, Leg. Med. 8 (2006) 166–171.
[9] U. Gutteck-Amster, K.M. Rentsch, Quantification of the aminosteroidal non-depolarizing neuromuscular blocking agent vecuronium and vecuronium in plasma with liquid chromatography-tandem mass spectroscopy, Clin. Chem. 46 (2000) 1413–1414.
[10] J. Ducharme, F. Varin, D.R. Bevan, F. Donati, Y. Theoret, High-performance liquid chromatography-electrochemical detection of vecuronium and its metabolites in human plasma, J. Chromatogr. 573 (1992) 79–86.
[11] O.Y. Hu, C.H. Chou, W. Ho, S.T. Ho, Determination of vecuronium in blood by HPLC with UV and electrochemical detection: a pilot study in man, Proc. Natl. Sci. Counc. Repub. China B 15 (1991) 186–190.
[12] J.E. Paanakker, J.M.S.L. Thio, H.M. Van Den Wildenberg, F.M. Kaspersen, Assay of vecuronium in plasma using solid phase extraction, high-performance liquid chromatography and post-column ion-pair extraction with fluorimetric detection, J. Chromatogr. B Biomed. Sci. Appl. 421 (1987) 327–335.
[13] M. Gasdag, M. Bahaj, P. Kerennes-Bakos, S. Gorog, Ion-pair high performance liquid chromatographic separation of quaternary ammonium steroid on silica, J. Chromatogr. 550 (1991) 639–644.
[14] P.L. Garcia, F.P. Gomez, M.I. Santoro, R.R. Kedor-Hackmann, J.L. Quero, A.N. Monton, G.C. Montoya, M.A. Cabrera, Determination of vecuronium bromide in pharmaceuticals: development, validation and comparative study of HPLC and CZE analytical methods, Chromatographia 73 (2011) 799–805.
[15] K. Petrà, P. Jác, V. Luková, J. Kunet, M. Polášek, Determination of muscle relaxants pancuronium and vecuronium bromide by capillary electrophoresis with capacitively coupled contactless conductivity detection, Electrophoresis 32 (2011) 890–895.
[16] T. Furuta, P.C. Canfell, K.P. Castagnoli, M.L. Sharma, R.D. Miller, Quantification of pancuronium, 3-desacetylpancuronium, vecuronium, 3-desacyetylvecuronium, piperucuron and 3-desacetylpipecuronium in biological fluids by capillary gas chromatography using nitrogen-sensitive detection, J. Chromatogr. A 427 (1988) 41–53.
[17] K.P. Castagnoli, Y. Shinozaka, T. Furuta, T.L. Nguyen, L.D. Gruenke, R.D. Miller, N. Castagnoli, Quantitative estimation of quaternary ammonium neuromuscular blocking agents in serum by direct insertion probe chemical ionization mass spectrometry, Biol. Mass Spectrom. 13 (1986) 327–332.
[18] T.R. Baker, P. Vouros, D. Rindgen, J.A. Martyn, Mass spectrometric assay for the determination of pancuronium and vecuronium in biological fluids utilizing the moving belt introduction system, Biomed. Environ. Mass Spectrom. 19 (1990) 69–74.
[19] K.C.H. Yiu, E.N.M. Ho, T.S.M. Wan, Detection of quaternary ammonium drugs in equine urine by liquid chromatography-mass spectrometry, Chromatographia 59 (2004) 545–550.
[20] M. Blessy, R.D. Patel, P.N. Prajapati, V.K. Agrawal, Development of forced degradation and stability indicating studies of drugs-A review, J. Pharmaceut. Anal. 4 (2014) 159–165.
[21] International Conference on Harmonization ICH Q1A (R2), Stability Testing of New Drug Substances and Drug Products, 2003.
[22] V.R. Sinha, A. Trehan, M. Kumar, S. Singh, J.R. Bhinge, Stress studies on acyclovir, J. Chromatogr. Sci. 45 (2007) 319–324.
[23] WHO. Methods of Analysis, physical and physicochemical methods, High performance liquid chromatography 1.14.4, 2019.
[24] Diana Fahem, Ola El Houssinia, Mohamed Abd El-Rahman, Hala E.Zaazaa, A point of care screen printed potentiometric sensor for therapeutic monitoring of vecuronium, Microchemical 147 (2019) 532–537.